Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Castration-resistant prostate cancer: where are we going?].
Alcaraz A, Medina R, Maroto P, Climent MÁ, Castellano D, Carles J. Alcaraz A, et al. Among authors: carles j. Actas Urol Esp. 2012 Jun;36(6):367-74. doi: 10.1016/j.acuro.2011.10.010. Epub 2011 Dec 19. Actas Urol Esp. 2012. PMID: 22188754 Review. Spanish.
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
Bellmunt J, Guillem V, Paz-Ares L, González-Larriba JL, Carles J, Batiste-Alentorn E, Sáenz A, López-Brea M, Font A, Nogué M, Bastús R, Climent MA, de la Cruz JJ, Albanell J, Banús JM, Gallardo E, Diaz-Rubio E, Cortés-Funes H, Baselga J. Bellmunt J, et al. Among authors: carles j. J Clin Oncol. 2000 Sep 15;18(18):3247-55. doi: 10.1200/JCO.2000.18.18.3247. J Clin Oncol. 2000. PMID: 10986057 Clinical Trial.
Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma.
Aparicio J, García del Muro X, Maroto P, Paz-Ares L, Alba E, Sáenz A, Terrasa J, Barnadas A, Almenar D, Arranz JA, Sánchez M, Fernández A, Sastre J, Carles J, Dorca J, Gumà J, Yuste AL, Germà JR; Spanish Germ Cell Cancer Cooperative Group (GG). Aparicio J, et al. Among authors: carles j. Ann Oncol. 2003 Jun;14(6):867-72. doi: 10.1093/annonc/mdg241. Ann Oncol. 2003. PMID: 12796024 Free article.
Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.
Carles J, Esteban E, Climent M, Font A, Gonzalez-Larriba JL, Berrocal A, Garcia-Ribas I, Marfa X, Fabregat X, Albanell J, Bellmunt J; Spanish Oncology Genito Urinary Group Study Group. Carles J, et al. Ann Oncol. 2007 Aug;18(8):1359-62. doi: 10.1093/annonc/mdm160. Ann Oncol. 2007. PMID: 17693649 Free article. Clinical Trial.
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.
Bellmunt J, González-Larriba JL, Prior C, Maroto P, Carles J, Castellano D, Mellado B, Gallardo E, Perez-Gracia JL, Aguilar G, Villanueva X, Albanell J, Calvo A. Bellmunt J, et al. Among authors: carles j. Ann Oncol. 2011 Dec;22(12):2646-2653. doi: 10.1093/annonc/mdr023. Epub 2011 Mar 21. Ann Oncol. 2011. PMID: 21427062 Free article. Clinical Trial.
[Recomendations on the management of controversies in advanced castrate-resistant prostate cancer].
Cózar JM, Solsona E, Morote J, Miñana B, Maroto JP, González Del Alba A, Climent MA, Carles J, Alcaraz A, Castellano D; Asociación Española de Urología; Grupo de Urología Oncológica; Grupo Español de Oncología Genitourinaria. Cózar JM, et al. Among authors: carles j. Actas Urol Esp. 2012 Nov-Dec;36(10):569-77. doi: 10.1016/j.acuro.2012.06.004. Epub 2012 Sep 19. Actas Urol Esp. 2012. PMID: 22999347 Spanish.
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.
de la Piedra C, Alcaraz A, Bellmunt J, Meseguer C, Gómez-Caamano A, Ribal MJ, Vázquez F, Anido U, Samper P, Esteban E, Álvarez-Ossorio JL, Lara PC, San José LA, Contreras JA, del Alba AG, González-Gragera B, Tabernero AJ, González-Enguita C, Fernández JM, García-Escudero A, Gómez-Veiga F, Méndez MJ, Segarra J, Virizuela JA, Carles J, Lassa A, Calderero V, Constela M, Delgado D, Mañas A, Murias A, Reynes G, Rodriguez B, Rubio G, Sánchez E, Unda M, Solsona E, Martínez-Javaloyas JM, Comet-Batlle J, Quicios C, Martín-Fernández M, Mahillo-Fernández I, Morote J. de la Piedra C, et al. Among authors: carles j. Br J Cancer. 2013 Jun 25;108(12):2565-72. doi: 10.1038/bjc.2013.270. Epub 2013 May 30. Br J Cancer. 2013. PMID: 23722472 Free PMC article. Clinical Trial.
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
Alcaraz A, González-López R, Morote J, de la Piedra C, Meseguer C, Esteban E, Climent M, González-Gragera B, Alvarez-Ossorio JL, Chirivella I, Mellado B, Lara PC, Vázquez F, Contreras JA, Carles J, Murias A, Calderero V, Comet-Batlle J, González-Del Alba A, León-Mateos L, Mañas A, Segarra J, Lassa A, González-Enguita C, Méndez MJ, Samper P, Unda M, Mahillo-Fernández I, Bellmunt J; TUGAMO GROUP. Alcaraz A, et al. Among authors: carles j. Br J Cancer. 2013 Jul 9;109(1):121-30. doi: 10.1038/bjc.2013.272. Epub 2013 Jun 25. Br J Cancer. 2013. PMID: 23799855 Free PMC article.
291 results